MEIP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MEIP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. MEI Pharma's Operating Income for the three months ended in Dec. 2023 was $-11.93 Mil. MEI Pharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, MEI Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.
Good Sign:
MEI Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for MEI Pharma's Operating Margin % or its related term are showing as below:
MEI Pharma's 5-Year Average Operating Margin % Growth Rate was 43.50% per year.
MEI Pharma's Operating Income for the three months ended in Dec. 2023 was $-11.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $15.88 Mil.
The historical data trend for MEI Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Operating Margin % | Get a 7-Day Free Trial | -940.90 | -92.58 | -173.65 | -185.48 | -75.31 |
MEI Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Operating Margin % | Get a 7-Day Free Trial | 27.27 | -278.10 | -760.47 | 84.66 | - |
For the Biotechnology subindustry, MEI Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, MEI Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
MEI Pharma's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as
Operating Margin % | = | Operating Income (A: Jun. 2023 ) | / | Revenue (A: Jun. 2023 ) |
= | -36.764 | / | 48.816 | |
= | -75.31 % |
MEI Pharma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as
Operating Margin % | = | Operating Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -11.93 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma (NAS:MEIP) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of MEI Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Taheer Datoo | director | 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3 |
James P Flynn | director | 41 HARRIS CT, DANVILLE CA 94526 |
Sujay Kango | director | 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807 |
Richard G Ghalie | officer: Chief Medical Officer | C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Bruce Ross Winson | 10 percent owner | 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225 |
Anson Funds Management Lp | 10 percent owner | 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248 |
Anson Management Gp Llc | 10 percent owner | 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248 |
Anson Advisors Inc. | 10 percent owner | 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7 |
Funicular Funds, Lp | 10 percent owner | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Amin Nathoo | 10 percent owner | 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7 |
Moez Kassam | 10 percent owner | 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1 |
Justin J. File | officer: CFO and Corporate Secretary | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Jacob Ma-weaver | 10 percent owner | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Cable Car Capital Llc | 10 percent owner | 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114 |
Baltic Charles V. Iii | director | C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130 |
From GuruFocus
By Business Wire • 11-02-2023
By Business Wire • 06-27-2023
By Business Wire • 10-17-2023
By Business Wire • 09-28-2023
By Business Wire • 07-05-2023
By Business Wire • 07-17-2023
By Business Wire • 10-02-2023
By GuruFocus Research • 09-23-2023
By Business Wire • 11-01-2023
By Business Wire • 12-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.